| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.70 [0.54, 0.91] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | crucial | - |
| deaths (OS) (extension) | 0.76 [0.60, 0.96] | | < 1 | | 0% | 1 study (1/-) | 99.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.77 [0.63, 0.95] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.77 [0.62, 0.96] | | < 1 | | 0% | 1 study (1/-) | 99.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 0.84 [0.56, 1.25] | | > 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
| objective responses (ORR) (extension) | 0.84 [0.56, 1.25] | | > 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 14.63 [0.82, 259.59] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.16 [0.77, 1.76] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.35 [0.11, 1.11] | | < 1 | | 0% | 1 study (1/-) | 96.3 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 3.96 [1.57, 9.99] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.12 [0.74, 1.70] | | < 1 | | 0% | 1 study (1/-) | 29.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.26 [0.78, 2.06] | | < 1 | | 0% | 1 study (1/-) | 17.4 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.56 [0.68, 3.56] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.02 [0.68, 1.52] | | < 1 | | 0% | 1 study (1/-) | 46.5 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.99 [0.20, 4.96] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 3.99 [0.18, 89.04] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.99 [0.02, 50.14] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.99 [0.02, 50.14] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.18 [0.66, 2.12] | | < 1 | | 0% | 1 study (1/-) | 28.9 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 3.99 [0.18, 89.04] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.98 [0.07, 59.51] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 3.99 [0.18, 89.04] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.99 [0.02, 50.14] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 4.02 [0.45, 36.30] | | < 1 | | 0% | 1 study (1/-) | 10.9 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 3.00 [0.31, 29.09] | | < 1 | | 0% | 1 study (1/-) | 17.3 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.48 [0.18, 1.30] | | < 1 | | 0% | 1 study (1/-) | 92.5 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.98 [0.07, 59.51] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 6.02 [0.30, 120.88] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.99 [0.02, 50.14] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.99 [0.02, 50.14] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.02, 50.14] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 4.02 [0.45, 36.30] | | < 1 | | 0% | 1 study (1/-) | 10.9 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.25 [0.48, 3.24] | | < 1 | | 0% | 1 study (1/-) | 32.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.99 [0.06, 15.94] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.98 [0.07, 59.51] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.91 [0.57, 1.44] | | < 1 | | 0% | 1 study (1/-) | 66.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.49 [0.04, 5.47] | | < 1 | | 0% | 1 study (1/-) | 71.6 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.33 [0.03, 3.17] | | < 1 | | 0% | 1 study (1/-) | 83.1 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 89.04] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 6.02 [0.30, 120.88] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.49 [0.04, 5.47] | | < 1 | | 0% | 1 study (1/-) | 71.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 8.06 [0.42, 153.52] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 0.99 [0.02, 50.14] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.36 [0.67, 2.73] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.66 [0.11, 3.97] | | < 1 | | 0% | 1 study (1/-) | 67.6 % | NA | not evaluable | | non important | - |
